Provisional data from the Centers for Disease Control and Prevention released in January 2026 show that U.S. drug overdose deaths continued a major decline through August 2025. An estimated 73,000 people died, a 21% drop from roughly 92,000 deaths the previous year. This follows a nearly 27% decline in 2024, bringing rates to their lowest since 2019, before the pandemic surge.
The decline was widespread. Forty five states reported fewer deaths, with only Arizona, Hawaii, Kansas, New Mexico, and North Dakota not showing reductions. Experts caution that deaths remain high compared to pre pandemic levels. Some early 2025 data showed a small temporary rise before numbers fell again.
Beyond opioids, other drugs influenced trends in the same 12 month period ending August 2025. Overdose deaths involving stimulants such as cocaine and methamphetamine rose by approximately 12%, often occurring with opioids. Experts attribute this increase to higher potency and contamination of stimulants with fentanyl or synthetic opioids, about 25% of all stimulants seized nationally contain these substances, inconsistent access to addiction treatment for stimulant users, and co use with opioids, which raises the risk of fatal overdose. Nonfatal overdoses, in which individuals experience life threatening symptoms but survive, were also tracked in emergency departments nationally to guide local response efforts.
Several factors contributed to the overall decline in drug overdose deaths. One is a possible temporary shortage of illicit fentanyl. Expanded access to naloxone, the overdose reversing drug, also helped. The FDA approved over the counter naloxone, and federal programs enabled community groups and first responders to distribute it more widely. Federal policies also played a key role. The SUPPORT for Patients and Communities Act expanded access to treatment, recovery programs, and prevention. Billions from opioid lawsuit settlements funded local treatment and harm reduction. The federal Public Health Emergency declaration allows flexibility in treatment and funding. New proposals such as the Modernizing Opioid Treatment Access Act aim to expand methadone access through pharmacies.
To address rising stimulant deaths, federal and state strategies are expanding. Evidence based behavioral treatments, such as contingency management, reward individuals for reducing or stopping stimulant use, and federal funding is increasing access to these programs. Harm reduction tools, including fentanyl test strips, are being distributed more widely to allow people who use stimulants to detect contamination. The CDC’s surveillance systems track stimulant overdoses in near real time to guide targeted local interventions. Federal initiatives through the White House Office of National Drug Control Policy aim to reduce methamphetamine and cocaine use disorders, increase access to treatment, and coordinate state and local prevention programs.
The White House Office of National Drug Control Policy also guides efforts to expand treatment, disrupt trafficking, and improve overdose data. Local programs funded by federal grants, including overdose mapping systems and Fatality Review Teams, help communities respond faster.
The decline is encouraging, but deaths remain high. Drug overdoses are still a leading cause of death among adults aged 18 to 44. Continued investment in treatment, prevention, harm reduction, and stimulant specific programs is essential to sustain progress and addressing evolving drug patterns nationwide.